2 active not recruiting, 1 recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
Follow Encoded Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Encoded Therapeutics | 113 | 2024-05-14 | 2026-10-23 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Active not recruiting | Encoded Therapeutics | 5 | 2024-05-09 | 2026-06-08 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Active not recruiting | Encoded Therapeutics | 4 | 2024-02-28 | 2025-11-14 |
Epilepsies, Myoclonic (3) · Generalized Epilepsy With Febrile Seizures Plus, Type 2 (2)
Australia (2) · United Kingdom (2) · United States (1)
Salvador Rico, M.D., Ph.D (2) · Salvador Rico, M.D., Ph. D (1)